The National Comprehensive Cancer Network has updated its clinical practice oncology guideline for lobular breast cancer to include the use of fluoroestradiol (FES)-PET for systemic staging.
The guideline now recommends that FES-PET be used in patients with recurrent or metastatic lobular breast cancer. The update was written by a group gathered by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and included SNMMI, Lobular Breast Cancer Alliance, American College of Nuclear Medicine, and Korean Society of Nuclear Medicine breast care specialists.
